GC
TAK icon

GMT Capital’s Takeda Pharmaceutical TAK Stock Holding History

GMT Capital’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-609,195
Closed -$8.3M – 77
2021
Q4 		$8.3M Sell
609,195
-41,800
-6% -$586K 0.64% 29
2021
Q3 		$10.7M Sell
650,995
-563,700
-46% -$9.46M 0.94% 26
2021
Q2 		$20.4M Sell
1,214,695
-1,254,000
-51% -$21.3M 1.53% 17
2021
Q1 		$45.1M Sell
2,468,695
-402,700
-14% -$7.25M 3.31% 10
2020
Q4 		$52.3M Buy
2,871,395
+238,100
+9% +$4.18M 3.73% 8
2020
Q3 		$47M Sell
2,633,295
-728,581
-22% -$13.3M 3.42% 8
2020
Q2 		$60.3M Sell
3,361,876
-209,200
-6% -$3.76M 3.39% 11
2020
Q1 		$54.2M Buy
3,571,076
+225,100
+7% +$4.08M 3.04% 9
2019
Q4 		$66M Buy
3,345,976
+193,506
+6% +$3.7M 2.55% 13
2019
Q3 		$54.2M Buy
3,152,470
+1,177,110
+60% +$20.4M 2% 15
2019
Q2 		$35M Buy
1,975,360
+397,400
+25% +$7.23M 1.22% 28
2019
Q1 		$32.1M Buy
+1,577,960
New +$31.8M 1.06% 32

Other funds holding TAK

PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

GMT Capital's TAK Position: Q1 2022 in Review

GMT Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 609,195 shares — an estimated $8.3M sold.

GMT Capital first reported a position in TAK in Q1 2019 and held it in 12 quarters. The position peaked at $66M in Q4 2019. 287 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

  • GMT Capital reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • GMT Capital sold 609,195 Takeda Pharmaceutical shares in Q1 2022, an estimated $8.3M.
  • GMT Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 12 quarters.
  • GMT Capital's Takeda Pharmaceutical position peaked at $66M in Q4 2019.
  • 287 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on GMT Capital's 13F filing for Q1 2022, filed 11 May 2022.